US FDA Seeks Patient Data Sheets For All New Scripts

3 September 1995

The US Food and Drug Administration has proposed that patients receive clear and simple information sheets about every medicine with all new prescriptions. Under the proposal, pharmacists would voluntarily offer patients new, comprehensive and clear information on all the 3,300 or so medicines currently available.

Secretary of Health and Human Services Donna Shalala said the scheme would require pharmacists to provide written information to 75% of patients receiving new prescriptions by the year 2000, and this should reach 95% 10 years after such a regulation went into effect. Should the quotas not be met, the brochure would become mandatory; to ensure the requirements are met, the FDA will conduct surveys asking whether patients are getting the inserts and if they are clear and complete. At present, only Texas requires written patient instructions with every prescription.

The Medication Guides would be developed under agency guidelines. A prototype two-page insert for an antibiotic, offered by the FDA as an example, included a box containing the most important information, followed by simple questions and answers about who should take the drug, how to take it, possible side effects and storage.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight